Skip to main content

Exelixis Q2 Net Loss Jumps on Increased Revenue

NEW YORK, Aug. 8 – Exelixis on Wednesday reported a second-quarter net loss of $23.7 million, or 30 cents per share, compared with $11.0 million, or 16 cents per share, during the comparable period last year despite posting a 54 percent surge in total revenue.

Wall Street had predicted a net loss of 31 cents per share, according to a poll of six brokers conducted by First Call/Thomson Financial.

In a statement, Exelixis attributed the higher loss to research and development fees and milestone payments from collaborations with various pharmaceutical companies. It added that it expects total expenses to continue climbing into the third quarter at a rate of 20 percent to 25 percent higher than second-quarter levels. The company predicted that third-quarter revenue would be 35 percent to 40 percent higher than second-quarter levels.

Revenue for the quarter ended June 30 increased by $3 million to $8.6 million from the second quarter one year ago, Exelixis said.

Expenses for the South San Francisco, Calif.-based company rose by 83 percent during the second quarter 2001 to $33.4 million from $18.3 million year over year.

The company also spent twice as much on R&D during the second quarter 2001 as it did during the same period last year, it said. In a statement, Exelixis said new collaborations, a new drug-discovery facility, and expanded drug-discovery efforts all contributed to higher R&D costs.

Exelixis’ general and administration expenses rose to $4.3 million from $3.6 million during the year-ago period. The company also incurred costs of $6.7 million for acquired in-process research and development. For example, in April, Exelixis acquired Cologne, Germany-based Artemis Pharmaceuticals in a stock-for-stock deal valued at $24 million.

Shares in Exelixis slipped $0.74 to close at $15.86 in Nasdaq trade on Wednesday.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.